Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among...
Transcript of Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among...
![Page 1: Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among patients diagnosed with tuberculosis, stratified by CD4 cell count at admission, Homa-Bay,](https://reader035.fdocuments.us/reader035/viewer/2022063012/5fc8a78dee53ff35cc7f31f2/html5/thumbnails/1.jpg)
Use of point-of-care viral load among critical populations
IDCSeptember 2019
![Page 2: Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among patients diagnosed with tuberculosis, stratified by CD4 cell count at admission, Homa-Bay,](https://reader035.fdocuments.us/reader035/viewer/2022063012/5fc8a78dee53ff35cc7f31f2/html5/thumbnails/2.jpg)
Diagnostics structureHIV and hepatitis laboratory structures have typically been very
centralized: molecular and immunological assays requiring significant infrastructure.
High quality, robust new technologies are allowing for greater decentralization and testing closer to the patient.
![Page 3: Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among patients diagnosed with tuberculosis, stratified by CD4 cell count at admission, Homa-Bay,](https://reader035.fdocuments.us/reader035/viewer/2022063012/5fc8a78dee53ff35cc7f31f2/html5/thumbnails/3.jpg)
Impact of POC testing – on identification and treatment initiation
HIV testingPOC CD4 for treatment initiation
POC EID
![Page 4: Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among patients diagnosed with tuberculosis, stratified by CD4 cell count at admission, Homa-Bay,](https://reader035.fdocuments.us/reader035/viewer/2022063012/5fc8a78dee53ff35cc7f31f2/html5/thumbnails/4.jpg)
Near point-of-care viral load technologies
For consideration in 2020 Consolidated Guidelines revision
![Page 5: Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among patients diagnosed with tuberculosis, stratified by CD4 cell count at admission, Homa-Bay,](https://reader035.fdocuments.us/reader035/viewer/2022063012/5fc8a78dee53ff35cc7f31f2/html5/thumbnails/5.jpg)
POC VL in general population
Drain P et al. CROI 2019
![Page 6: Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among patients diagnosed with tuberculosis, stratified by CD4 cell count at admission, Homa-Bay,](https://reader035.fdocuments.us/reader035/viewer/2022063012/5fc8a78dee53ff35cc7f31f2/html5/thumbnails/6.jpg)
High viral suppression rates across countries
Key questions:
1) How might this change with DTG?
2) How do we best manage those unsuppressed to reduce transmission and improve patient health?
![Page 7: Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among patients diagnosed with tuberculosis, stratified by CD4 cell count at admission, Homa-Bay,](https://reader035.fdocuments.us/reader035/viewer/2022063012/5fc8a78dee53ff35cc7f31f2/html5/thumbnails/7.jpg)
POC VL
Pregnant women
Advanced disease
Suspected failing
Re-entering
care
Infants and
children
What is the impact of POC VL?There is currently no WHO recommendation to use point-of-care or near point-of-care technologies for treatment monitoring; however, impact studies and implementation considerations are ongoing.
![Page 8: Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among patients diagnosed with tuberculosis, stratified by CD4 cell count at admission, Homa-Bay,](https://reader035.fdocuments.us/reader035/viewer/2022063012/5fc8a78dee53ff35cc7f31f2/html5/thumbnails/8.jpg)
Advanced disease: a persistent problem
Calmy CID 2018Ousley CID 2018
IeDEA cohort 2018
![Page 9: Use of point-of-care viral load among critical …...Homa-Bav Kinshasa Figure 1. Mortality among patients diagnosed with tuberculosis, stratified by CD4 cell count at admission, Homa-Bay,](https://reader035.fdocuments.us/reader035/viewer/2022063012/5fc8a78dee53ff35cc7f31f2/html5/thumbnails/9.jpg)
Questions?